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   The discovery of induced pluripotent stem (iPS) cells have opened the doors for further dis-
ease research, drug screening, as well as regenerative medicine. To achieve clinical application
of iPS cells, it is important to select proper iPS cell lines that do not harbor the risk of tumorige-
nicity. Thus, it is desired to establish methodologies for evaluating the safety of iPS cells, par-
ticularly in terms of genome integrity. Massively parallel sequencing can be used to monitor
genomic aberrations such as the subchromosomal and the single nucleotide variations. Refined
mutation analyses of iPS and founder cells revealed that some of the iPS cell-specific variations
were also detected in rare populations of the founder cells by consequence of capturing the
heterogeneity of the founder cells. In this review, we highlight recent analyses used to evaluate
the genome integrity of iPS cells, discuss future of directions for precise assessment of the
safety of iPS cells, and address issues that should be overcome.
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Introduction
   Induced pluripotent stem (iPS) cells are generated by the
enforced expression of transcription factors, most commonly
Oct3/4, Sox2, c-Myc and Klf4. In addition to pluripotency,
iPS cells have infinite capacity for self-renewal1-3). The char-
acteristics of fully reprogrammed cells are functionally and
molecularly very similar to those of embryonic stem (ES)
cells in terms of their morphologies, gene expression pro-
files, and capacities to differentiate into any of the follow-
ing three germ layers: endoderm, mesoderm, and ecto-
derm. iPS cells could be a useful source for cell transplan-
tation therapy, drug screening, and disease modeling4, 5).
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However, it is necessary to assess the risk of tumorigenic-
ity of ES, iPS, and multipotent stem cells6).
   Several pioneering gene therapies using transduced he-
matopoietic cells showed aberrant activation of adjacent
proto-oncogenes by retroviral vector insertion, resulting in
formation of cancers such as leukemia7-12). The first gen-
eration of iPS cells was established by the vector-integra-
tion method, which may also cause genotoxicity via heri-
table and potentially toxic or deleterious effect on genomic
DNA3).
   To avoid insertional genotoxicity in retroviral-induced iPS
cells, non-integration delivery methods using plasmids,
RNA, and proteins have been developed13). However, the
insertional genotoxicity is not the only issue to be resolved.
Several cell divisions with DNA replication during genera-
tion of iPS cells and their maintenance may expose cells to
the risk of genomic aberrations, including DNA mutations
and structural alterations. Such genomic aberrations of ES
and iPS cells may not only affect tumorigenicity but also
stem cell identity and differentiation capacity14, 15). The most
appropriate assessment is in vivo experimentation by ortho-
topic injection of the cells into animal models. The mouse
model is easily accessible, but it is difficult to approximate
whether this model can recapture the environment of hu-
man tumors. A monkey model may be preferred for analo-
gous assay to human tumor model; however, there are
drawbacks such as low-throughput screening and ethical
issues in the use of primates. Thus, instead of in vivo ap-
proaches, genomic analysis of iPS cells prior to clinical use
is essential to assess the risk of tumorigenicity.
   Recent advances in massively parallel sequencing have
facilitated to rapidly obtain large amounts of sequencing
data with simultaneous semi-terabase information. This
sequencing has enabled high-resolution and -throughput
assessment of DNA copy number variations (CNVs) and
single nucleotide variations (SNVs), to identify a series of
genetic diseases and other health-related traits16). For ex-
ample, several consortia have identified a large number of
cancer-specific mutations, including possible targets of anti-
cancer drugs17). In addition, several studies have recently
examined CNVs and SNVs of iPS cells using massively
parallel sequencer14, 15).
Aneuploidy and Subchromosomal Varia-
tions
   CNVs may affect the properties of ES and iPS cells
through perturbing gene expression profiles with altered
gene dosages. A previous study identified one iPS cell clone
with a distinctly different gene expression profile, prolifera-
tion rate, and differentiation potential to hematopoietic lin-
eage compared with all other iPS cell lines18). Thus, it is
important to select proper iPS cell lines that do not harbor
hazardous CNVs. The International Stem Cell Initiative
consortium addressed genomic alterations of pluripotent
stem cells using 125 human ES and 11 iPS cell lines19).
They reported that one-third of ES and iPS cell lines had
karyotype abnormalities, whereas another study demon-
strated that approximately 13% of ES and iPS cell lines
had abnormal karyotypes20). This consortium and other
studies have identified frequent duplications of chromo-
somes 12 and 20 in whole or in part, and less frequent
trisomy of chromosomes 8 and X19-21). In addition, trisomy
17 has been frequently observed in human ES cells, but
not in iPS cells20, 21). DNA copy number analysis of mouse
iPS cells also detected CNVs at chromosome 11 that in-
cluded conserved synteny regions with human chromo-
some 17, supporting the contention that human chromo-
some 17 is mechanically sensitive to DNA copy number
alteration of pluripotent stem cells22). These observations
imply that some selective pressures induce CNVs during
reprogramming. The other studies reported that prolonged
culture of the cells decreases the number and size of
CNVs23, 24) and indicated that prolonged culture exposed
the cells to selection pressure. For example, CNV analysis
of 22 iPS cell lines, three donor fibroblasts, and 17 ES cell
lines has previously revealed that reprogrammed popula-
tions at very early passage had extensive genomic mosa-
icism with CNVs, and continued passage decreased the
number and size of CNVs23).
SNVs
   The first study, which performed whole exome sequenc-
ing of 22 iPS cell lines, reported that approximately six SNVs
in protein-coding regions were detected in each iPS cell
line25) and that their mutations were highly observed in
proto-oncogenes registered in the Catalogue of Somatic
Mutations in Cancer (COSMIC) database26). On the other
hand, recent reports did not observe any significant en-
richment of cancer-related mutations in iPS cell-specific
SNVs27, 28). Because they used cord blood-derived iPS cell
lines generated by episomal vector method, source of iPS
cells and generation method may affect mutation event as
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discussed below.
   As well as genomic mosaicism with different CNVs24, 29, 30),
several studies reported that some of SNVs, which were
detected only in iPS cells by rough exome sequencing, were
also detected in rare populations of founder cells25, 27, 30).
Therefore, it is important to clarify whether SNVs or CNVs
detected by rough screening with massively parallel se-
quencing are truly iPS cell-specific or already existed in a
rare population of the founder cells. Ji et al.30) performed
sequencing of the same iPS cell line at different passages
and simulated a mutation rate of fibroblasts and iPS cells.
This study demonstrated that in vitro passaging contrib-
uted 7% of the mutations in iPS cells and ultra-deep se-
quencing showed that 19% of the mutations were pre-ex-
isting in the parental fibroblasts, where the remaining 74%
of the mutations were acquired during the reprogramming
process. The observed increase in the number of muta-
tions with prolonged culture and the mutation rate calcu-
lated in silico were consistent with an earlier report25).
iPS Cell Captured the Heterogeneity of
the Founder Cells
    There is an increasing evidence that human somatic cells
exhibit heterogeneity in genomic sequences31, 32). Although
several previous studies reported iPS cell-specific CNVs18,
19, 21, 23, 24, 29, 33, 34), the genetic mosaicism existing in the
founder cells should be considered to identify true iPS cell-
specific CNVs. Abyzov et al.29) detected iPS cell-specific
CNVs by whole-genome and transcriptome analyses of 20
human iPS cell lines and seven parental fibroblasts. How-
ever, by a more refined analysis using droplet digital PCR,
at least 50% of those CNVs were also presented in small
populations of parental fibroblasts from which each corre-
sponding iPS cell line was derived25). They also suggested
widespread mosaicism in human somatic cells by estimat-
ing that approximately 30% of fibroblasts had somatic
CNVs. Thus, a comparison to the founder cells is essential
to identify true iPS cell-specific CNVs.
   It remains controversial whether iPS cell-specific SNVs
and CNVs are consequence of selective pressure and also
facilitate reprogramming. Several studies repored that the
SNVs and CNVs observed only in iPS cells but not in the
founder cells may be consequences of selective pressure
during reprogramming30, 35). For example, mutation intensity
during reprogramming was nine-fold higher than the back-
ground mutation rate in culture30). On the other hand, one
reported that de novo mutations that could not be detected
in the founder cells appeared to arise randomly during re-
programming because no common mutations were ob-
served even among isogenic iPS cell lines25). Another study
reported that iPS cell-specific SNVs in exonic regions were
independent of the original cell type and thus supported
the notion that mutation events occurred randomly36). And
they could not observe any changes in efficiency of iPS
cell generation even when genes with iPS cell-specific
SNVs were silenced or over-expressed during reprogram-
ming36). In addition, the traditional kernel density estima-
tion to detect SNVs harbored in rare populations was used
to monitor heterogeneity, but failed to identify shared SNVs
in any clones in two of three experiments31). These find-
ings supported that iPS cell-specific SNVs were unlikely to
provide a selective advantage for reprogramming.
   A comparative analyses for iPS cells using both repro-
grammed cells and the corresponding fibroblasts or blood
cells are feasible, however, it is difficult to do the same
using human ES cell lines because they are produced by
culturing inner cell masses of donated blastocysts and thus
their genetic informationof the founder cells is generally
inaccessible. In addition, although clones of iPS cells are
generally derived from a single somatic cell, the ES cell
line is composed of multiple subclones37). Thus, it is hard
to identify ES cell-specific genomic variations.
Single-cell Analysis of SNVs and CNVs
   Although conventional karyotyping by G-banding can
detect chromosomal abnormalities at the single-cell level,
the results are occasionally not reproducible because judg-
ment of the karyotyping depends on the skill of observers
and the relatively small number of cells (generally up to
100). Thus, objective examination of karyotyping, such as
single cell analyses of SNVs and CNVs, is eagerly desired.
   Single-cell sequencing for CNV and SNV analysis con-
tinues to rapidly progress. For example, multiple displace-
ment amplification (MDA) followed by whole-genome se-
quencing has been applied for single-cell CNV detection.
Navin et al.38) were the first to report single-cell CNV analy-
sis using breast cancer tissues and cell lines. They ob-
served different patterns of CNVs in among each single
cell from the same cancer tissues or cell lines, and proposed
that, in contrast to gradual models of tumor progression,
tumors grow by punctuated clonal expansion with few per-
sistent intermediates. A second study reported the devel-
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opment of a new amplification method composed of mul-
tiple annealing and looping-based amplification cycles39).
This method was able to detect not only CNVs but also
SNVs at the single-cell level. In addition, McConnell et al.40)
performed single cell CNV analysis of human neuronal cells
by both single-nucleotide polymorphism (SNP) array-based
analysis and whole-genome sequencing. They found that
13% to 41% of neuronal cells had de novo CNVs (>1Mb),
indicating that CNVs were abundantly existed in human
neurons.
   Although SNV and CNV analyses at the single-cell level
are supposedly the best methods for precise assessment
of tumorigenic risk, these single-cell genome analyses are
currently utilized only in pre-clinical trials. The sequence
cost for such high-resolution SNV and CNV analyses us-
ing a portion of individual cells, for example with more than
100 single cells, is not reasonable at the present time. How-
ever, it is expected that the sequence cost will decrease
for clinical use in the near future, as the cost performance
of sequencing over the last decade has outpaced that pre-
dicted by Moore’s law, which describes the computing in-
dustry’s trend of doubling computer power every 2 years41).
In addition, genotyping of two alleles from a single cell re-
quires relatively lower sequence depth such as >10× ,
whereas that of bulk population generally requires a se-
quence depth of >30× .
Technical Concerns
   Optimizing culture conditions and methods for iPS cell
generation may reduce iPS cell-specific SNVs and CNVs.
For example, the number of iPS cell-specific SNVs were
decreased when ZSCAN4, which maintains genomic sta-
bility of pluripotent stem42, 43) and reprograming cells28, 44),
was overexpressed. Cheng et al.27) demonstrated that
reprograming of human cord blood (CB) CD34+ cells using
episomal vectors was a preferable method for iPS cell gen-
eration. They could not detect any iPS cell-specific CNVs
in three iPS cell lines even when cells cultured up to 51
passages27), whereas others found iPS cell-specific CNVs
in a part of iPS cell lines generated from fibroblast by inte-
grating viral vectors23, 24, 33). Not only CNVs but also SNVs
in CB-derived iPS cell lines was observed much less than
those in iPS cells derived from fibroblasts or marrow stro-
mal cells (MSCs)27, 28). One of the possibilities for less ge-
nomic alterations in CB-derived iPS cells is because paren-
tal CB CD34+ cells are obtained after less expansion of the
cells than adult fibroblasts. Another possibility is that CB
CD34+ cells are more homogenous population than fibro-
blasts that are highly exposed to environmental insults45, 46).
   The most considerable issue of sequence-based analy-
sis is sequencing bias. High GC regions are difficult to se-
quence and highly repetitive sequences are hard to map
to the human genome. The current sequencing technol-
ogy cannot cover all exonic regions, even though sequenc-
ing with higher read depth broadens sequenceable exonic
regions, however, further advancements in sequencing
technology may overcome these issues. In addition to com-
plete sequencing of exonic regions, it may be necessary
to perform whole genome sequencing because extra-ex-
onic SNVs may play a role in the efficiency of iPS cell gen-
eration, differentiation, and tumorigenicity.
   For CNV analyses, sequence-based approaches may
capture relatively small size of CNVs, which cannot be de-
tected by SNP array-based analysis. This sequence-based
strategy requires high sequence coverage in general, but
a pipeline for single-cell CNV detection with low sequence
coverage has been recently developed47). Moreover, im-
provements in the algorithms for the other structural alter-
ations such as breakpoints of translocations are anticipated.
For example, the progress in longer sequence reads will
undoubtedly improve the efficiency of detecting such struc-
tural alterations.
   There are other technical issues to overcome with these
sequence-based analyses, particularly in bioinformatical
analyses. Several algorithms to identify genomic variations
using sequencing data have been developed, but there
remain serious discrepancies among different pipelines for
calling SNVs and small insertions/deletions48). Thus, im-
proved accuracy of variation calling is eagerly desired,
particularly when dealing with low sequence read depth
from whole genome sequencing of a single cell. Refined
analyses by amplicon-sequencing for target regions could
be also helpful to increase the accuracy of these meth-
ods30, 48).
Future Perspectives
   There is a vast amount of information on cancer-associ-
ated mutations in the literatures and from large-scale
screenings conducted by international consortia17). Com-
parisons of observed iPS cell-specific SNVs to mutations
in the COSMIC database have been conducted to predict
causal mutations linked to tumorigenesis25, 27, 28). However,
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the list of deposited mutations is incomplete. The COSMIC
database is composed of not only driver mutations but also
resultant SNVs that do not contribute to tumor develop-
ment or progression. In addition, as we discussed above,
the list of cancer-associated genes may include SNVs
arisen from clonal expansion of individual non-cancerous
cells. And one cannot make conclusions before consider-
ing the functional contribution of SNVs to tumorigenesis
because different histories of tumorigenesis exhibit diverse
mutations.
   The number and the position of SNVs and CNVs ac-
quired during the reprogramming process and whether
these variations affect the efficiency of reprogramming, tu-
morigenesis, or differentiation potential should be consid-
ered. Because the major concern for the clinical applica-
tion of iPS cells is their propensity to form tumors, several
studies assessed the risk of tumorigenesis by characteris-
tics of the SNVs49, 50). It is unreasonable to perform func-
tional assays for every iPS cell-specific genomic variation
because it is labor intensive and time consuming. Rapid
progress in computational approaches can be used to pre-
dict biological consequence of altered protein function due
to amino acid substitutions51). Combinations of experimen-
tal evidence with in silico prediction would be helpful to
predict hazardous genomic variations of iPS cells.
   Besides surveys of SNVs by comprehensive analyses
such as exome and whole-genome sequencing, detailed
SNV analysis of cancer-related genes is important because
very few cells in minor populations may harbor mutations
that cause tumorigenesis. Ultra-deep sequencing of PCR
amplicons can achieve a highly sensitive detection of SNVs,
i.e., 0.01% existing in very small cell populations. iPS cells
that present a risk of tumorigenesis could be ruled out by
the ultra-deep sequencing of target regions such as previ-
ously reported proto-oncogenes and tumor suppressor
genes.
   Several previous studies focused on SNVs and CNVs of
iPS cells, however, it is important to perform SNV and CNV
analyses of differentiated cells that will be applied for trans-
plantation. The risk of tumorigenicity of iPS cells for allo-
transplantation as well as autologous transplantation should
be also assessed by SNV and CNV analyses of iPS cells
and their related founder cells. And genomic mosaicism of
the iPS cell clone and iPS cell-derived differentiated cells
should be evaluated because previous studies indicated 3
to 30 mutations per haploid genome were acquired in one
mitotic division27, 52).
   In this review, we summarized recent reports on the ge-
nome integrity of iPS cells. It is critical to analyze CNVs
and SNVs to examine the genome integrity of both iPS
cells and related founder cells because it has been shown
that some CNVs and SNVs observed only in iPS cells are
consequences of cloning of the individual founder cells.
Massively parallel sequencing technology is rapidly pro-
cessing. Single-cell CNV and SNV analyses to assess the
risk of genotoxicity of iPS cells for clinical applications are
eagerly desired. Concomitantly with facilitating progress
of sequencing technologies, improvement of in silico ap-
proaches including expanding and refining databases
should be emphasized. The strategy for combining experi-
mental evidences by sequencing and precise in silico pre-
diction represents a basis of risk assessment of cell mate-
rials for regenerative medicine.
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